Tag Archives: shpg

Shire Lifts 2015 Guidance On Strong Drug Pipeline

Shire (SHPG) missed analysts’ targets for second-quarter earnings and sales but lifted its outlook, citing a strong drug pipeline. The Irish drugmaker’s adjusted Q2 earnings per share fell a penny to 88 cents, missing by 5 cents. Operating income on a non-GAAP basis fell 3% to $614 million, below Wall Street views for $670 million. Revenue rose 4% to $1.56 billion, short of consensus for $1.58 billion, as the strength of the U.S. dollar cut sales

Valeant Earnings Soar On M&A, Organic Sales Growth

Acquisition-hungry Valeant Pharmaceuticals (VRX) rose more than 5% in the stock market today to a record high, despite weak Q3 earnings guidance, after neatly stepping over analysts’ second-quarter revenue and earnings expectations. Valeant was one of several drugmakers and biotechs to report Thursday morning, including Celgene (CELG), Eli Lilly (LLY), Shire (SHPG) and Bristol-Myers Squibb (BMY) . The Laval, Quebec-based drugmaker said total

Meet 8 Hot Med Stocks Among IBD’s Big Cap Leaders

IBD’s Big Cap Leaders screen filters through highly liquid, large-cap stocks with a strong record of earnings growth. Eight top-notch medical stocks that made the screen’s cut are Valeant Pharmaceuticals (VRX), Gilead Sciences (GILD), Celgene (CELG), Actavis (ACT), Biogen (BIIB), Regeneron (REGN), Shire (SHPG) and Illumina (ILMN). Valeant Pharmaceuticals has a highest-possible IBD Composite Rating of 99, meaning its shares outperform 99% of all